vs
Side-by-side financial comparison of CF Industries (CF) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
CF Industries is the larger business by last-quarter revenue ($2.0B vs $1.2B, roughly 1.7× Jazz Pharmaceuticals plc). CF Industries runs the higher net margin — 31.0% vs 17.0%, a 14.0% gap on every dollar of revenue. On growth, CF Industries posted the faster year-over-year revenue change (19.4% vs 10.1%). CF Industries produced more free cash flow last quarter ($1.7B vs $345.8M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 12.4%).
CF Industries Holdings, Inc. is an American manufacturer and distributor of agricultural fertilizers, including ammonia, urea, and ammonium nitrate products. The company is based in Northbrook, Illinois, a suburb of Chicago, and was founded in 1946 as the Central Farmers Fertilizer Company. For its first 56 years, it was a federation of regional agricultural supply cooperatives. CF then demutualized, and became a publicly traded company.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
CF vs JAZZ — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.2B |
| Net Profit | $615.0M | $203.5M |
| Gross Margin | 37.6% | — |
| Operating Margin | 43.5% | 21.2% |
| Net Margin | 31.0% | 17.0% |
| Revenue YoY | 19.4% | 10.1% |
| Net Profit YoY | 97.1% | 6.5% |
| EPS (diluted) | $3.98 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.7B | $897.8M | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.6B | $1.0B |
| Q1 26 | $615.0M | — | ||
| Q4 25 | $495.0M | $203.5M | ||
| Q3 25 | $460.0M | $251.4M | ||
| Q2 25 | $492.0M | $-718.5M | ||
| Q1 25 | $351.0M | $-92.5M | ||
| Q4 24 | $392.0M | $191.1M | ||
| Q3 24 | $341.0M | $215.1M | ||
| Q2 24 | $506.0M | $168.6M |
| Q1 26 | 37.6% | — | ||
| Q4 25 | 40.9% | — | ||
| Q3 25 | 38.1% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 34.4% | — | ||
| Q4 24 | 34.4% | — | ||
| Q3 24 | 32.4% | — | ||
| Q2 24 | 43.2% | — |
| Q1 26 | 43.5% | — | ||
| Q4 25 | 33.0% | 21.2% | ||
| Q3 25 | 35.0% | 5.1% | ||
| Q2 25 | 34.3% | -65.6% | ||
| Q1 25 | 27.4% | -6.2% | ||
| Q4 24 | 28.9% | 17.5% | ||
| Q3 24 | 26.6% | 24.7% | ||
| Q2 24 | 40.6% | 19.5% |
| Q1 26 | 31.0% | — | ||
| Q4 25 | 26.4% | 17.0% | ||
| Q3 25 | 27.7% | 22.3% | ||
| Q2 25 | 26.0% | -68.7% | ||
| Q1 25 | 21.1% | -10.3% | ||
| Q4 24 | 25.7% | 17.6% | ||
| Q3 24 | 24.9% | 20.4% | ||
| Q2 24 | 32.2% | 16.5% |
| Q1 26 | $3.98 | — | ||
| Q4 25 | $2.56 | $3.34 | ||
| Q3 25 | $2.19 | $4.08 | ||
| Q2 25 | $2.37 | $-11.74 | ||
| Q1 25 | $1.85 | $-1.52 | ||
| Q4 24 | $1.86 | $2.97 | ||
| Q3 24 | $1.55 | $3.42 | ||
| Q2 24 | $2.30 | $2.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.4B |
| Total DebtLower is stronger | $3.2B | $5.4B |
| Stockholders' EquityBook value | $5.3B | $4.3B |
| Total Assets | $14.6B | $11.7B |
| Debt / EquityLower = less leverage | 0.60× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $5.4B | ||
| Q3 25 | $3.0B | $5.4B | ||
| Q2 25 | $3.0B | $5.4B | ||
| Q1 25 | $3.0B | $5.4B | ||
| Q4 24 | $3.0B | $6.1B | ||
| Q3 24 | $3.0B | $6.1B | ||
| Q2 24 | $3.0B | $5.7B |
| Q1 26 | $5.3B | — | ||
| Q4 25 | $4.8B | $4.3B | ||
| Q3 25 | $4.8B | $4.0B | ||
| Q2 25 | $5.0B | $3.7B | ||
| Q1 25 | $4.8B | $4.2B | ||
| Q4 24 | $5.0B | $4.1B | ||
| Q3 24 | $5.2B | $4.2B | ||
| Q2 24 | $5.5B | $3.8B |
| Q1 26 | $14.6B | — | ||
| Q4 25 | $14.1B | $11.7B | ||
| Q3 25 | $14.2B | $11.4B | ||
| Q2 25 | $13.8B | $10.9B | ||
| Q1 25 | $13.3B | $11.5B | ||
| Q4 24 | $13.5B | $12.0B | ||
| Q3 24 | $13.8B | $12.3B | ||
| Q2 24 | $13.8B | $11.4B |
| Q1 26 | 0.60× | — | ||
| Q4 25 | 0.66× | 1.24× | ||
| Q3 25 | 0.61× | 1.35× | ||
| Q2 25 | 0.60× | 1.45× | ||
| Q1 25 | 0.62× | 1.29× | ||
| Q4 24 | 0.60× | 1.49× | ||
| Q3 24 | 0.57× | 1.47× | ||
| Q2 24 | 0.54× | 1.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $496.0M | $362.5M |
| Free Cash FlowOCF − Capex | $1.7B | $345.8M |
| FCF MarginFCF / Revenue | 83.2% | 28.9% |
| Capex IntensityCapex / Revenue | 11.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.81× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $3.0B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $496.0M | — | ||
| Q4 25 | $539.0M | $362.5M | ||
| Q3 25 | $1.1B | $474.6M | ||
| Q2 25 | $563.0M | $88.9M | ||
| Q1 25 | $586.0M | $429.8M | ||
| Q4 24 | $420.0M | $398.6M | ||
| Q3 24 | $931.0M | $398.7M | ||
| Q2 24 | $475.0M | $331.4M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $313.0M | $345.8M | ||
| Q3 25 | $717.0M | $459.4M | ||
| Q2 25 | $318.0M | $75.9M | ||
| Q1 25 | $454.0M | $415.9M | ||
| Q4 24 | $223.0M | $385.3M | ||
| Q3 24 | $792.0M | $388.0M | ||
| Q2 24 | $391.0M | $324.3M |
| Q1 26 | 83.2% | — | ||
| Q4 25 | 16.7% | 28.9% | ||
| Q3 25 | 43.2% | 40.8% | ||
| Q2 25 | 16.8% | 7.3% | ||
| Q1 25 | 27.3% | 46.3% | ||
| Q4 24 | 14.6% | 35.4% | ||
| Q3 24 | 57.8% | 36.8% | ||
| Q2 24 | 24.9% | 31.7% |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.1% | 1.4% | ||
| Q3 25 | 20.9% | 1.3% | ||
| Q2 25 | 13.0% | 1.2% | ||
| Q1 25 | 7.9% | 1.5% | ||
| Q4 24 | 12.9% | 1.2% | ||
| Q3 24 | 10.1% | 1.0% | ||
| Q2 24 | 5.3% | 0.7% |
| Q1 26 | 0.81× | — | ||
| Q4 25 | 1.09× | 1.78× | ||
| Q3 25 | 2.31× | 1.89× | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.67× | — | ||
| Q4 24 | 1.07× | 2.09× | ||
| Q3 24 | 2.73× | 1.85× | ||
| Q2 24 | 0.94× | 1.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CF
| EBITDA | $1.0B | 51% |
| Other | $975.0M | 49% |
| Loss on foreign currency transactions | $3.0M | 0% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
